Shares of Second Sight Medical Products Inc (NASDAQ:EYES) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price target of $5.00 for the company and are anticipating that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Second Sight Medical Products an industry rank of 92 out of 257 based on the ratings given to its competitors.
Several brokerages have weighed in on EYES. HC Wainwright set a $5.00 target price on Second Sight Medical Products and gave the stock a “buy” rating in a research report on Thursday. ValuEngine raised Second Sight Medical Products from a “hold” rating to a “buy” rating in a research report on Friday, November 2nd. Finally, Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th.
Shares of Second Sight Medical Products stock traded down $0.07 on Thursday, reaching $1.63. 1,800 shares of the company were exchanged, compared to its average volume of 179,265. The firm has a market capitalization of $117.38 million, a PE ratio of -2.76 and a beta of 2.91. Second Sight Medical Products has a fifty-two week low of $1.13 and a fifty-two week high of $2.58.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Wednesday, November 7th. The medical device company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. The firm had revenue of $2.25 million for the quarter, compared to analyst estimates of $2.48 million. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. As a group, equities analysts anticipate that Second Sight Medical Products will post -0.58 earnings per share for the current fiscal year.
About Second Sight Medical Products
Second Sight Medical Products, Inc develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
Recommended Story: Understanding the different types of bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.